Diwu Weilong, Tang Wenhao, Yan Ming, Ma Wenrui, Han Yisheng, Yang Min
Department of Orthopedics, Xijing Hospital of Air Force Medical University, Xi'an, Shaanxi, China.
Int J Surg Protoc. 2025 Aug 7;29(3):122-127. doi: 10.1097/SP9.0000000000000056. eCollection 2025 Sep.
Postoperative pain management remains a critical determinant of functional recovery following total knee arthroplasty (TKA). While local infiltration analgesia (LIA) is commonly employed, its clinical utility is limited by inconsistent analgesic duration (median duration of 8-12 hours), technical variability among surgeons, and systemic toxicity risks associated with high-volume injections. This phase II randomized controlled trial evaluates a dual-optimization strategy combining anatomic mapping-guided periarticular cutaneous nerve (PCN) blockade with a sustained-release triamcinolone-ropivacaine formulation to address these limitations.
In this single-center, assessor-blinded, 2 × 2 factorial design, 120 adults undergoing primary unilateral TKA were randomized to four intervention arms: Group 1: Conventional iPACK (interspace between the popliteal artery and posterior knee capsule) site + novel formulation (1% ropivacaine + 40 mg triamcinolone); Group 2: PCN block site + standard formulation (1% ropivacaine + 5 mg dexamethasone); Group 3: PCN block + novel formulation; Group 4: Control (iPACK + standard formulation). Triamcinolone acetonide replaces dexamethasone in the new formulation due to its prolonged anti-inflammatory effect and demonstrated efficacy in periarticular analgesia. Primary endpoints included: resting/movement-induced pain intensity (Visual Analog Scale) at 6, 24, and 48 h postoperatively, cumulative opioid consumption (morphine milligram equivalents), functional recovery metrics (knee flexion angle, Timed Up-and-Go test). Secondary outcomes assessed safety through adverse event rates (infection, neurologic symptoms, hemodynamic instability).
Anatomic mapping-guided PCN blockade combined with triamcinolone-ropivacaine formulation significantly improves postoperative analgesia and functional outcomes compared to conventional LIA techniques. This dual-optimization approach may redefine periarticular infiltration standards in TKA, particularly for patients at high risk of opioid-related complications.
全膝关节置换术(TKA)后疼痛管理仍然是功能恢复的关键决定因素。虽然局部浸润镇痛(LIA)被广泛应用,但其临床效用受到镇痛持续时间不一致(中位持续时间为8 - 12小时)、外科医生技术差异以及大容量注射相关的全身毒性风险的限制。这项II期随机对照试验评估了一种双重优化策略,该策略将解剖图谱引导的关节周围皮神经(PCN)阻滞与缓释曲安奈德 - 罗哌卡因制剂相结合,以解决这些局限性。
在这项单中心、评估者盲法的2×2析因设计中,120例接受初次单侧TKA的成年人被随机分为四个干预组:第1组:传统腘动脉后间隙(iPACK)部位 + 新型制剂(1%罗哌卡因 + 40毫克曲安奈德);第2组:PCN阻滞部位 + 标准制剂(1%罗哌卡因 + 5毫克地塞米松);第3组:PCN阻滞 + 新型制剂;第4组:对照组(iPACK + 标准制剂)。由于曲安奈德具有延长的抗炎作用且在关节周围镇痛中已证明有效,因此在新制剂中用曲安奈德代替地塞米松。主要终点包括:术后6、24和48小时的静息/运动诱发疼痛强度(视觉模拟量表)、累积阿片类药物消耗量(吗啡毫克当量)、功能恢复指标(膝关节屈曲角度、计时起立行走测试)。次要结局通过不良事件发生率(感染、神经症状、血流动力学不稳定)评估安全性。
与传统LIA技术相比,解剖图谱引导的PCN阻滞联合曲安奈德 - 罗哌卡因制剂显著改善了术后镇痛和功能结局。这种双重优化方法可能会重新定义TKA中的关节周围浸润标准,特别是对于有阿片类药物相关并发症高风险的患者。